{
    "clinical_study": {
        "@rank": "3359", 
        "arm_group": {
            "arm_group_label": "DEB-TACE", 
            "arm_group_type": "Experimental", 
            "description": "Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):\nDoxorubicin-loaded LC Beads\u00ae are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
        }, 
        "brief_summary": {
            "textblock": "TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of\n      diminishing hepatic tumor burden while patients await transplantation. Without this\n      therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ\n      allocation.\n\n      The purpose of the study is to determine whether transarterial chemoembolization using\n      doxorubicin-eluting beads (DEB-TACE) can be used safely and effectively to treat patients\n      with liver-only hepatocellular carcinoma (HCC) and baseline hepatic dysfunction."
        }, 
        "brief_title": "TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve", 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Chemoembolization"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult male or female patients, age 18 years of age or older\n\n          2. Diagnosis of liver-only HCC based on European Association for the Study of the Liver\n             (EASL) criteria (radiographic lesion appearance on contrast-enhanced CT or MRI, i.e.\n             enhancement on early arterial phase, washout on portal venous phase with or without\n             associated elevation of serum AFP level >200U/ml) or histologic confirmation of HCC\n             diagnosis, whichever is applicable.\n\n          3. UNOS stage T1, T2, or T3 disease.\n\n          4. Candidates for liver transplantation (listed or screened) according to one of the\n             following criteria:\n\n               1. Milan criteria (one lesion < 5cm or 3 or fewer lesions each < 3cm),\n\n               2. UCSF Downstaging criteria (one lesion less than 8 cm or 2-3 lesions each less\n                  than 5 cm with sum of maximum dimensions less than 8 cm, or 4-5 lesions each\n                  less than 3 cm with sum of maximum dimensions less than 8 cm)\n\n               3. UCSF All-Comers criteria (UNOS stage T3 disease beyond UCSF Downstaging\n                  Criteria).\n\n          5. At least one measurable site of disease in the liver according to RECIST version 1.1\n             and mRECIST criteria.\n\n          6. At least one of the following clinical, laboratory, or imaging parameters:\n\n               1. Mild or moderate ascites\n\n               2. Serum bilirubin \u2265 3 mg/dl but less than 6 mg/dl\n\n               3. Aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) but < 10\n                  times ULN\n\n               4. Alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN) but < 10\n                  times ULN\n\n               5. International normalized ratio for prothrombin time (INR) >1.5 but \u2264 2.5\n\n               6. Portal vein thrombosis (branch or main)\n\n               7. Functioning transjugular intrahepatic portosystemic shunt (TIPS) or surgical\n                  portosystemic shunt\n\n          7. ECOG performance status of 0, 1, or 2.\n\n        Exclusion Criteria:\n\n          1. Liver-directed therapy (chemoembolization, radioembolization, bland embolization,\n             ablative therapy) within 4 weeks of DEB-TACE.\n\n          2. Previous liver transplantation.\n\n          3. Serum bilirubin \u2265 6 mg/dl\n\n          4. AST > 10 times upper normal limit\n\n          5. ALT > 10 times upper normal limit\n\n          6. INR > 2.5\n\n          7. Serum creatinine > 1.5 mg/dl\n\n          8. Macrovascular tumor invasion of portal and/or hepatic vein(s)\n\n          9. Extracapsular tumor extension\n\n         10. Extrahepatic disease\n\n         11. Hepatic encephalopathy refractory to medical therapy\n\n         12. Active uncontrolled infection\n\n         13. Imaging evidence of common bile duct obstruction\n\n         14. Previous sphincterotomy or bilio-enteric anastomosis\n\n         15. Significant hepatic arterial to portal vein shunting in the area to be treated.\n\n         16. Symptomatic congestive heart failure (CHF)\n\n         17. Allergy to or intolerance of prior doxorubicin-based TACE\n\n         18. Allergy to or intolerance to iodinated contrast media despite standard of care\n             pre-medication\n\n         19. Any contraindications to treatment with LC Bead\u2122 device (e.g. patients with large\n             diameter arteriovenous shunts or patients with a right-to-left shunt).\n\n         20. Systemic therapy with sorafenib or other systemic chemotherapeutic agent(s) less than\n             1 week prior to first planned DEB-TACE.\n\n         21. Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in\n             situ.  (Patients with history of malignancy are not considered to have a \"currently\n             active\" malignancy if they have completed therapy and are now considered by their\n             physician to be at less than 30% risk for relapse.)\n\n         22. Uncontrolled intercurrent illness including, but not limited to: Ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris,\n             uncontrolled cardiac arrhythmia, uncontrolled peripheral vascular disease, myocardial\n             infarction within preceding 12 months, cerebrovascular accident within preceding 12\n             months, pulmonary disease impairing functional status or requiring oxygen, impairment\n             in gastrointestinal function that may affect or alter absorption of oral medications\n             (such as malabsorption or history of gastrectomy or bowel resection).\n\n         23. Pregnant or lactating women are excluded from this study because of the potential for\n             teratogenic or abortifacient effects.  Because there is an unknown but potential risk\n             for adverse events in nursing infants secondary to treatment of the mother with\n             DEB-TACE, breastfeeding must be discontinued for eligibility.\n\n         24. Psychiatric illness, other significant medical illness, or social situation which, in\n             the investigator's opinion, would limit compliance or ability to comply with study\n             requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147301", 
            "org_study_id": "UCSF CC#124520"
        }, 
        "intervention": {
            "arm_group_label": "DEB-TACE", 
            "description": "Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):\nDoxorubicin-loaded LC Beads\u00ae are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first.", 
            "intervention_name": "LC Bead", 
            "intervention_type": "Device", 
            "other_name": "DC Bead"
        }, 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "curt.johanson@ucsf.edu", 
                "last_name": "Curt Johanson", 
                "phone": "415-353-2310"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "University of California San Francisco"
            }, 
            "investigator": {
                "last_name": "Nicholas Fidelman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve", 
        "overall_contact": {
            "email": "curt.johanson@ucsf.edu", 
            "last_name": "Curt Johanson", 
            "phone": "415-353-2310"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Radiographic response rate to DEB-TACE by conventional and modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, mRECIST) for treated lesions", 
                "measure": "Radiographic response rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured by RECIST v 1.1 and mRECIST", 
                "measure": "Overall radiographic response", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "TTUP is defined as time to disease progression untreatable by liver-directed percutaneous or surgical methods.", 
                "measure": "Time to untreatable progression (TTUP)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Hepatic progression free survival (HPFS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Proportion of patients who remain active on the wait list for a liver transplant and eventually are transplanted.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Proportion of patients who are inactivated or drop out from the wait list for any reason but transplantation.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Proportions of patients who are successfully down-staged and achieve active wait list status and eventually are transplanted", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Proportion of patients with alpha-fetoprotein (AFP) response with \u2265 50% decline from baseline (in patients with baseline level \u2265 20) post DEB-TACE and test for association with hepatic and overall response rate, PFS, and OS", 
                "measure": "Proportion of patients with alpha-fetoprotein (AFP) response with \u2265 50% decline from baseline", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Cardiac function changes by echocardiography", 
                "measure": "Cardiac function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "First 17 patients, first TACE procedure only", 
                "measure": "Area Under Curve (AUC), Time Frame: predose, 5 min, 20 min, 40 min, 60 min, 120 min, 6 hours, 24 hours, 7 days", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}